Characteristics of patients
| Parameters . | N . |
|---|---|
| Number of patients | 55 |
| Sex, male/female | 24/31 |
| Age, median year (age range) | 32 (6-59) |
| Interval between diagnosis and BMT, median mo (range in mo) | 13 (4-89) |
| Clinical phase at BMT | |
| Chronic phase | 47 |
| Accelerated phase and blast crisis | 6/2 |
| Donor type | |
| HLA-identical sibling | 50 |
| HLA-matched, unrelated | 5 |
| Preparative regimen | |
| CY + TBI | 39 |
| CY + BU | 16 |
| GVHD prophylaxis | |
| CsA | 21 |
| CsA + MTX | 34 |
| T-cell depletion | 11 |
| Acute GVHD (grades II-IV) | 11 |
| Chronic GVHD | |
| Limited | 12 |
| Extensive | 10 |
| Parameters . | N . |
|---|---|
| Number of patients | 55 |
| Sex, male/female | 24/31 |
| Age, median year (age range) | 32 (6-59) |
| Interval between diagnosis and BMT, median mo (range in mo) | 13 (4-89) |
| Clinical phase at BMT | |
| Chronic phase | 47 |
| Accelerated phase and blast crisis | 6/2 |
| Donor type | |
| HLA-identical sibling | 50 |
| HLA-matched, unrelated | 5 |
| Preparative regimen | |
| CY + TBI | 39 |
| CY + BU | 16 |
| GVHD prophylaxis | |
| CsA | 21 |
| CsA + MTX | 34 |
| T-cell depletion | 11 |
| Acute GVHD (grades II-IV) | 11 |
| Chronic GVHD | |
| Limited | 12 |
| Extensive | 10 |
CY indicates cyclophosphamide; TBI, total body irradiation; BU, busulphan; CsA, cyclosporine; and MTX, methotrexate.